12:00 AM
 | 
Jan 29, 2007
 |  BioCentury  |  Product Development

Ophthalmic reprofilers

Ophthalmic reprofilers

Ophthalmic reprofilers
For a number of companies in the ophthalmic space, an important component of their strategy is to take compounds that have been developed for other indications and reprofile them with an ophthalmic focus.
Company Description
Aerie Aerie’s discovery platform incorporates its pro-drug technology to increase drug delivery through the cornea and enables FDA-approved drugs to be repurposed for the treatment of eye diseases. Lead...

Read the full 368 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >